Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
South Korea's bio-industry increased its value output by 16.2 percent to 12.32 trillion won in 2019 from 10.48 trillion won the previous year due to robust growth of the outsourced business.
According to data from the Korea Biotechnology Industry Organization, the value of outsourced services that include contract research organization (CRO) and contract manufacturing organization (CMO) businesses jumped 21.1 percent on-year.
South Korea's exports of bioproducts, which rose 28.1 percent on-year to 6.71 trillion won in 2019, largely contributed to the value output.
The exports consisted of biomedicine products accounting for 39 percent, followed by bio-related food at 35.8 percent, and bio services at 12.2 percent.
The exports of cytokine products, including biosimilars, surged 50.7 percent on-year in 2019.
